




PASSION FOR PATIENTS

Positive Quality Interventions in Action

NCODA, INC.

Ginger Blackmon, PharmD – Senior Manager of Clinical Initiatives, NCODA and Dianna Phi-Linh Nguyen PharmD Candidate – University of Minnesota College of Pharmacy



Background

- NCODA’s Positive Quality Intervention (PQI) is a peer-reviewed clinical guidance resource for healthcare providers that was created in an effort to promote high quality patient care
- The PQI fosters better care for patients through appropriate patient identification, treatment selection, increased speed to therapy, reduced cost and hospitalization, and improved adherence techniques for the patient and their medically integrated teams
- By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics
- The PQI in Action incorporates opinions and experiences from oncology experts within the medically integrated teams at leading cancer care organizations
- These organizations have successfully implemented Medically Integrated Pharmacies (MIP) as well as the use of PQIs throughout their care teams to improve the clinical outcomes of patients

Objectives

- Evaluate benefits of the Medically Integrated Pharmacy (MIP) model
- Discuss strategies for increasing multidisciplinary team communication and interaction via PQI implementation
- Identify improved practices and positive patient outcomes that resulted from implementation of the principles found within the PQI

Methods

- Pinpoint NCODA member organizations with a Medically Integrated Pharmacy (MIP) model
- Interview multiple disciplines of staff to understand the various perspectives
- Examine how the principles of the NCODA PQI have been implemented across the MIP team
- Emphasize effective and valuable practices
- Determine positive patient outcomes that resulted from PQI implementation

Resources Overview

- Four Case Studies:
 - 1) Management for Advanced Systemic Mastocytosis
 - 2) Treatment of Relapsed/Refractory Follicular Lymphoma
 - 3) Genomic Testing and Therapy Management in RET-Altered Cancers
 - 4) Treatment of HER2-Positive Breast Cancer
- Interviews with the Cancer Care Organizations:
 - 1) Cancer Specialists of North Florida (CSNF) & O’Neal Comprehensive Cancer Center at The University of Alabama (UAB)
 - 2) Tennessee Cancer Specialists & Utah Cancer Specialists (UCS)
 - 3) Moffitt Cancer Center, Smilow Cancer Center at Yale New Haven Health & Texas Oncology
 - 4) Rocky Mountain Cancer Centers (RMCC) & Cancer Care Associates of York (CCAY)
- Information Collection and Authorship:
 - Ginger Blackmon, PharmD; Natasha Olson, PharmD; Kristie Fox, PharmD; and Tahsin Imam, PharmD
- Distribution via online promotion, meeting presentations, and printed materials for NCODA members


Discussion

- Traditionally, pharmacists act as a primary source for medication information
- However, any member of the care team may be a key contributor to increasing awareness of medication therapy options and appropriate management
- PQIs encourages proactive intervention through multidisciplinary team interaction
- PQI implementation may vary between organizations depending upon EMR, organizational structure, etc.
- Improved patient outcomes are evident with treatment selection and therapy management
- Standardization empowers the entire MIP team to consistently improve care

Conclusion

- PQIs provide concise, high-quality clinical guidance information
- PQIs standardize a particular aspect of oncology care for an organization
- All members of the MIP team report benefits from the PQI resource
- PQI in Action interviews and articles illustrate methods for adoption of the PQI into practice and highlights how leading oncology organizations benefit from the resource
- Individual patients have benefited from adoption of the principles found within the PQI:
 - **Avapritinib:** Gives patients with advanced systemic mastocytosis a new targeted treatment option
 - **Tazemetostat:** Assess therapy management and help patients avoid financial toxicities
 - **Selpercatinib:** Details genomic testing and relevant dose adjustments to navigate potential adverse reactions
 - **Neratinib:** Fosters ongoing communication, education, and involvement to help clinical teams help patients manage side effects, improve compliance, and be self-advocates in their care

PQI in Action




AVAPRITINIB (AYVAKIT®) MANAGEMENT FOR ADVANCED SYSTEMIC MASTOCYTOSIS



TAZEMETOSTAT (TAZVERIK®) MANAGEMENT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA



SELPERCATINIB (RETEVMO®) GENOMIC TESTING AND MANAGEMENT



NERATINIB (NERLYNX®) DIARRHEA MANAGEMENT



NCODA'S POSITIVE QUALITY INTERVENTION IN ACTION



NCODA'S POSITIVE QUALITY INTERVENTION IN ACTION



NCODA'S POSITIVE QUALITY INTERVENTION IN ACTION



NCODA'S POSITIVE QUALITY INTERVENTION IN ACTION

NOW STREAMING

Follow Us On Instagram @thepqipodcast



Listen on Apple Podcasts

Spotify NCODA.org

Information

NCODA PQI Clinical Committee

- Jody Agena, PharmD, MBA, BCOP
- Virginia Cancer Specialists, VA
- Jen Hasiak, PharmD
- Hematology & Oncology Consultants Pharmacy, NE
- Loan Lam, PharmD
- Polyclinic, WA
- Natasha Olson, PharmD
- NCODA
- Jasmine Patel, PharmD, BCOP
- Boston Medical Center, MA
- Raquel Rhone, PharmD
- Texas Oncology, TX
- Jon Suyko, PharmD
- UC Health Highlands Ranch, CO
- Lauren Trisler, PharmD, BCOP
- Florida Cancer Center, FL

NCODA PQI Clinical Committee Chairs

- Kirollos Hanna, PharmD, BCPS, BCOP – Chief Editor
- University of Minnesota Medical Center, MN
- Mayo Clinic, MN
- Kayla Boyd, PharmD, BCOP
- Kaiser Permanente, GA
- Michelle Phillips, PharmD, BCOP
- UR Specialty Pharmacy, NY
- NCODA PQI Physician Medical Reviewers**
- Lawrence Garbo, MD
- New York Oncology Hematology, NY
- Wayne Ormsby, MD
- Utah Cancer Specialists, UT

Digital PQI in Action articles can be found online here:

